As number of COVID-19 cases in Russia crossed 500,000, the government has rolled out a drug to treat the novel coronavirus even though clinical trials are still underway.
The country's health ministry has approved the use of the anti-viral drug, registered under the name Avifavir, under a special accelerated process.
In a press release, the state financial backer said the drug has been delivered to some hospitals and clinics in the country.
The country's RDIF sovereign wealth fund has a 50 per cent share in a joint venture with the drug's manufacturer ChemRar.
There is currently no vaccine for COVID-19, with human trials of several existing antiviral drugs yet to show efficacy.
So far, the country has 502,436 positive cases and the death toll stands at 6,532.


Trump says Iran's 'present' to US was allowing 10 oil tankers through Hormuz
Iran sees US peace plan as 'one-sided' as Trump presses for deal
Ukraine's Zelenskyy arrives in Saudi Arabia for 'important meetings'
US jury verdicts against Meta, Google tee up fight over tech liability shield
Iran says it is reviewing US proposal to end war
24 dead after bus falls into river while boarding ferry in Bangladesh
UN Human Rights Council adopts resolution condemning Iranian attacks
273 million children out of school in 2026 UNESCO report
